Novartis lifts FY 2026 core operating income guidance after Q3 sales rise and $1.9 bn impairment
Novartis reported third‑quarter 2026 net sales of $14.522 billion, up 4% year‑on‑year, and core operating income of $6.036 billion, up 11% in USD terms. A $1.9 billion partial impairment on the del‑desiran asset drove reported operating income down 59% and net income down 70%. The company raised its full‑year core operating income outlook to low single‑digit growth, while keeping its sales growth forecast unchanged.
Why it matters
The upgraded guidance signals that Novartis expects modest profit growth for FY 2026 despite a sharp drop in reported earnings, which may support the stock’s valuation. However, the large impairment reduces cash generation and could pressure near‑term free cash flow, as noted by the company’s own release.
Key facts
- 1Q3 net sales were USD 14,522 million, up 4% in both USD and constant‑currency terms from USD 13,909 million a year earlier. securities.io
- 2Core operating income rose to USD 6,036 million, a 11% increase in USD (10% in constant currency). securities.io
- 3Core operating income margin was 41.6% of net sales, a rise of 2.3 percentage points (2.0 pp in constant currency). securities.io
- 4A partial impairment of the del‑desiran asset was recorded at USD 1.9 billion. securities.io
- 5Core earnings per share were USD 2.46, up 9% in constant currency. securities.io
- 6Free cash flow for the quarter was USD 5.111 billion, down 18% year‑on‑year. securities.io
Summary written by AlphAI AI Desk from 20 of 42 sources. Not investment advice. Figures are as stated by the linked sources.